

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
08 May 2025 (08.05.2025)



(10) International Publication Number
WO 2025/096687 A1

(51) International Patent Classification:

A61K 31/7125 (2006.01) A61K 39/395 (2006.01)
A61K 9/00 (2006.01) A61P 35/00 (2006.01)
A61K 38/16 (2006.01) C12N 15/117 (2010.01)

(21) International Application Number:

PCT/US2024/053756

(22) International Filing Date:

30 October 2024 (30.10.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/546,445 30 October 2023 (30.10.2023) US

(71) Applicant: TRISALUS LIFE SCIENCES, INC.

[US/US]; 6272 West 91st Avenue, Westminster, CO 80031 (US).

(72) Inventors: KATZ, Steven, C.; 150 Fernwood Drive, East

Greenwich, RI 02818 (US). KIM, Alexander; 9000 Erving Drive, Bethesda, MD 20817 (US).

(74) Agent: LEE, Wan Chieh; Haug Partners LLP, 745 Fifth

Avenue, 10th Floor, New York, NY 10151 (US).

(81) Designated States (unless otherwise indicated, for every

kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every

kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: METHODS OF TREATING PANCREATIC DUCTAL ADENOCARCINOMA WITH A TOLL-LIKE RECEPTOR 9 AGONIST




FIG. 1

(57) Abstract: A method of treating pancreatic ductal adenocarcinoma (PDAC) in a human subject is provided. The method comprises locally administering a toll-like receptor 9 (TLR9) agonist to a human subject in need thereof. The TLR9 agonist is an oligonucleotide having the sequence: 5'-TCG AAC GTT CGA ACG TTC GAA CGT TCG AAT-3' (SEQ ID NO: 1), or a pharmaceutically acceptable salt thereof. Specifically, the TLR9 agonist is nelitolimod.

[Continued on next page]

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))